摘要
目的探讨胺碘酮联合达比加群酯治疗非瓣膜性心房颤动的疗效和安全性。方法将2014年1月至2014年7月收治的76例非瓣膜性心房颤动患者随机分为治疗组和对照组,治疗组予以胺碘酮联合达比加群酯治疗,对照组予以胺碘酮联合华法林,观察凝血指标变化,心电图、生化指标变化和不良反应等情况。结果与治疗前相比,治疗后两组凝血酶原时间(PT)、凝血活酶时间(APTT)、国际标准化比值(INR)、凝血酶时间(TT)均升高(P<0.05)。治疗后,两组间各凝血指标比较,差异无统计学意义(P>0.05),两组患者心率明显降低(P<0.05),其他心电图表现均无明显变化(P>0.05)。治疗组发生消化道反应9例(23.7%),高于对照组的5.3%(P<0.05)。而治疗组栓塞或血栓以及出血的发生率均低于对照组(P<0.05)。结论胺碘酮联合达比加群酯治疗非瓣膜性心房颤动安全有效,值得在临床推广。
Objective To investigate the efficacy and safety of amiodarone combined with dabigatran etexilate in the treatment of non-valvular atrial fibrillation.Methods 76 cases of non-valvular atrial fibrillation in our hospital from January to July 2014 were randomly divided into the treatment group and the control group.The treatment group was treated with amiodarone combined with dabigatran etexilate,while the control group was treated with amiodarone combined with warfarin.The changes of electrocardiogram（EKG）,blood coagulation indexes and biochemical indexes,and adverse reactions were observed in the two groups.Results Compared with before treatment,PT,APTT,INR and TT after treatment in the two groups were increased（P〈0.05）.After treatment,the coagulation indexes had no statistical differences between the two groups（P〉0.05）,the heart rate in the two groups was significantly decreased（P〈0.05）,other ECG manifestations showed no significant changes（P〉0.05）.9cases（23.7%）of gastrointestinal reactions occurred in the treatment group,which were higher than 5.3%in the control group（P〈0.05）.But the occurrence rate of embolism or thrombosis and hemorrhage in the treatment group was lower than that in the control group（P〈0.05）.Conclusion Amiodarone combined with dabigatran etexilate is effective and safe in the treatment of non-valvular atrial fibrillation,and is worth spreading and using in clinic.
出处
《检验医学与临床》
CAS
2015年第14期1997-1998,共2页
Laboratory Medicine and Clinic
基金
重庆市自然科学基金重点项目(cstc2012jjB10020)
关键词
胺碘酮
达比加群酯
心房颤动
dabigatran
amiodarone
atrial fibrillation
作者简介
李玲，女，硕士研究生，主治医师，主要从事心血管内科工作。
通讯作者，E-mail：whysir@aliyun．com。
